415 related articles for article (PubMed ID: 17252021)
1. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
Thomas X; Raffoux E; Botton Sd; Pautas C; Arnaud P; de Revel T; Reman O; Terré C; Corront B; Gardin C; Le QH; Quesnel B; Cordonnier C; Bourhis JH; Elhamri M; Fenaux P; Preudhomme C; Michallet M; Castaigne S; Dombret H
Leukemia; 2007 Mar; 21(3):453-61. PubMed ID: 17252021
[TBL] [Abstract][Full Text] [Related]
2. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
Wörmann B; Hiddemann W; Frisch J; Zühlsdorf M; Rottmann R; Boeckmann A; Reuter C; Freire EA; Innig G; Schulz G
Behring Inst Mitt; 1991 Dec; (90):28-38. PubMed ID: 1801688
[TBL] [Abstract][Full Text] [Related]
4. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study.
Thomas X; Raffoux E; Renneville A; Pautas C; de Botton S; Terre C; Gardin C; Hayette S; Preudhomme C; Dombret H
Cancer; 2010 Apr; 116(7):1725-32. PubMed ID: 20143449
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
Thomas X; Fenaux P; Dombret H; Delair S; Dreyfus F; Tilly H; Vekhoff A; Cony-Makhoul P; Leblond V; Troussard X; Cordonnier C; de Revel T; Simon M; Nicolini F; Stoppa AM; Janvier M; Bordessoule D; Rousselot P; Ffrench M; Marie JP; Archimbaud E
Leukemia; 1999 Aug; 13(8):1214-20. PubMed ID: 10450749
[TBL] [Abstract][Full Text] [Related]
6. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
He XY; Pohlman B; Lichtin A; Rybicki L; Kalaycio M
Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371
[TBL] [Abstract][Full Text] [Related]
7. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
8. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
[TBL] [Abstract][Full Text] [Related]
10. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
Löwenberg B; van Putten W; Theobald M; Gmür J; Verdonck L; Sonneveld P; Fey M; Schouten H; de Greef G; Ferrant A; Kovacsovics T; Gratwohl A; Daenen S; Huijgens P; Boogaerts M; ;
N Engl J Med; 2003 Aug; 349(8):743-52. PubMed ID: 12930926
[TBL] [Abstract][Full Text] [Related]
11. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
12. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Thomas X; Suciu S; Rio B; Leone G; Broccia G; Fillet G; Jehn U; Feremans W; Meloni G; Vignetti M; de Witte T; Amadori S
Haematologica; 2007 Mar; 92(3):389-96. PubMed ID: 17339189
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
14. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
[TBL] [Abstract][Full Text] [Related]
15. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
16. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
17. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
[TBL] [Abstract][Full Text] [Related]
18. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy in childhood acute myeloid leukemia.
Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
[TBL] [Abstract][Full Text] [Related]
20. Pilot remission induction therapy with idarubicin, plus an intensified dose of ara-C and priming with granulocyte colony-stimulating factor for acute myeloid leukemia.
Baek JH; Sohn SK; Kim DH; Kim JG; Yang DH; Kim YK; Lee JJ; Kim HJ
Acta Haematol; 2007; 117(2):109-14. PubMed ID: 17135724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
